RIDDLE&CODE
RIDDLE&CODE Energy Solutions, a 50:50 joint venture between Wien Energie and RIDDLE&CODE, has joined the 2Tokens consortium as a founding member for the Energy Token working group. After having been an associated partner since 2020, the company’s decision to become an active contributor is a consequent step on its path to developing an international service portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005131/en/
The main goal of the collaboration is to turn 2Tokens into the leading European consortium in the industrial blockchain and finance space, representing and supporting the most relevant projects. "We have proven the technical and economic viability of tokenizing energy assets in several individual projects at the regional level. Now it is time to think on a larger scale. The token standards being developed at 2Tokens will most likely have a decisive impact on the future standards of the European energy market,” says Kai Siefert, the newly appointed managing director of RIDDLE&CODE Energy Solutions.
“The joining of a true pioneer such as RIDDLE&CODE Energy Solutions will significantly strengthen European collaboration in the tokenization sector,” underlines Alex Bausch, Executive Chairman of 2Tokens. “RIDDLE&CODE Energy Solutions plays an important role in the adoption of tokenization technology in commercial projects with interoperable banking grade solutions. Our working groups on the EURO stable coin and Energy Tokens are paramount to the joint mission for mass adoption of token technology in the energy industry. “
Next steps: Apart from driving things forward in the 2Tokens working groups, leading 2Tokens members, as well as the RIDDLE&CODE group companies, will discuss commercial partnerships in the areas of Custody of Digital Assets, Tokenization platforms and blockchain hardware research. "For critical infrastructures and in order to turn our European values of democratic governance and the Rule of Law into efficient backend solutions, we need infrastructure that is secure from end-to-end. Crypto hardware anchors will play a key role in this, and that's why 2Tokens is excited to have RIDDLE&CODE joining as the leading European blockchain interface company,” says Jos Röling, Captain of the Energy working group.
About RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions provides the blockchain-powered infrastructure that enables resilient, decentralized and fully decarbonized energy markets. With the development of the MyPower platform, the company has shown an effective way for energy players to move into the machine economy. By tokenizing energy, machines, and data, RIDDLE&CODE Energy Solutions significantly increases the liquidity of distributed assets, making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
About 2Tokens
2Tokens has the ambition to raise awareness, stimulate relevant discussions, and bring together knowledge/expertise to reduce the barriers to the adoption of tokenization and help realise wider social benefits. The mission of 2Tokens is to formulate a guide, as part of a larger vision, for any type of organisation that wants to leverage token technology. It aims to come to a shared understanding of token finance and, as such, is a public-interest initiative supported by a diverse community of technology companies, policymakers, financial advisors, banks, and legal & regulatory experts and academia. 2Tokens is a non-profit organisation funded in part by the European Union and Industry partners with the endorsement of the Erasmus University Rotterdam, government and several industry players.
More information: www.2tokens.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom